drugset / Trial / NCT01728623

A Study of E7080 in Subjects With Advanced Thyroid Cancer

NCT01728623 ↗

Phase 2 Completed 51 enrolled Eisai Inc.
NaSingle-groupOpen-labelTreatment

Summary

This study is to evaluate the safety, efficacy, and pharmacokinetics of E7080 when orally administered once daily (QD) in subjects with advanced thyroid cancer.

Timeline

Start
2012-09-03
Primary completion
2015-07-09
Completion
2015-10-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Lenvatinib Small molecule 24 mg Oral

Indications